ARCA biopharma, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | 0 | 0% |
| P/S |
|
0 | 33.76 | -100% |
|
|
| P/BV |
|
0.6659 | 4.82 | -86.19% |
|
|
| P/FCF |
|
0 | 61 | -100% |
|
|
| Ev/Ebitda |
|
1.71 | -22.15 | -107.73% |
|
|
| Ev/S |
|
0 | 22.56 | -100% |
|
|
| Ev/FCF |
|
2.49 | 68.78 | -96.38% |
|
|
| E/P |
|
0 | 0.0178 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 4.98 | -100% | -7751.05 | -100% |
| ROE |
|
-14.42 | 9.61 | -250.05% |
|
|
| ROA |
|
-14.1 | 0.3443 | -4196.21% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
0 | -25.17 | -100% |
|
|
| ROCE |
|
-19.71 | 15.35 | -228.39% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.0384 | -3.68 | -98.96% | -0.0323 | +18.69% |
| Nеt Debt/Ebitda |
|
5.09 | -3.44 | -248.16% |
|
|
| Debt/Ratio |
|
0.0074 | 0.1985 | -96.27% |
|
|
| Debt/Equity |
|
0 | 1.66 | -100% |
|
|
| Debt/Net Income |
|
-0.0524 | 10.32 | -100.51% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
10/10
|
66.25 | 0.5442 | 12073.49% | 33.13 | +100% |
| Number of years of dividend growth |
|
1 | 0.7368 | 35.71% | ||
| DSI |
|
1 | 0.2237 | 347.06% |
|
|
| Average dividend growth |
|
99.38 | 0.9889 | 9948.96% |
|
|
| Average percentage for 5 years |
|
33.13 | 0.4952 | 6588.68% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
65.71 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
7721.03 | -56.89 | -13671.86% | ||
| Growth impulse Ebitda in 5 years |
|
30.29 | -54.68 | -155.4% | ||
| Growth impulse Net Income in 5 years |
|
-2.93 | -58.33 | -94.98% | ||
| Growth impulse FCF in 5 years |
|
4.46 | -49.48 | -109.01% | ||
| Growth impulse EPS in 5 years |
|
-91.08 | -32.41 | 181.02% |
IP Score
4.71/10
